TICKERNERD
Menu
MLYSMLYSHealthcare · Biotechnology

MLYS Stock Forecast: Mineralys Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$26
+1.02% on the day

The 10 Wall Street analysts covering Mineralys Therapeutics, Inc. hold a median 12-month price target of $52 — +101.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.2B
Ticker Nerd rank
37 / 100
Median analyst target
$52
Analysts covering
10
Total return, dividends reinvested
1W
−5.3%
1M
−6.9%
YTD
−29.0%
1Y
+88.7%
From 52W high
−45.5%
From 52W low
+100.3%
$13
$47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MLYS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Mineralys Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
70
Momentum
68
Value
59
Quality
50
Revisions
48
Size
34
Issuance
33
Volatility
27
Accruals
26

Growth (70): Sales and profits are climbing, and climbing faster than before.

Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

The rank is the raw material. Whether the rules would actually own Mineralys Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

MLYS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MLYS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26MLYSHigh $56Median $52Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $30Median $52High $56

The green dot is the last close — the median target sits +101.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Apr 2026TD CowenInitiatesBuy—
27 Apr 2026TD CowenInitiatesBuy—
13 Mar 2026B of A SecuritiesMaintainsBuy—
19 Dec 2025StifelMaintainsBuy—
12 Nov 2025HC Wainwright & Co.MaintainsBuy—
11 Nov 2025Wells FargoMaintainsOverweight—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
11 Sept 2025Wells FargoMaintainsOverweight—
9 Sept 2025Goldman SachsMaintainsBuy—
8 Sept 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025JefferiesMaintainsHold—
28 Aug 2025B of A SecuritiesMaintainsBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
17 June 2025HC Wainwright & Co.ReiteratesBuy—
11 June 2025JefferiesInitiatesHold—
13 May 2025HC Wainwright & Co.ReiteratesBuy—
2 Apr 2025HC Wainwright & Co.MaintainsBuy—
10 Mar 2025HC Wainwright & Co.ReiteratesBuy—
24 Feb 2025GuggenheimReiteratesBuy—
13 Feb 2025Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

MLYS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
6
Fundamentals

Mineralys Therapeutics, Inc. (MLYS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.1×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
3.3×

Cheaper than 31% of US stocks

EV / EBITDA
−8.5×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−31.0%

Higher than 26% of US stocks

Return on assets
−21.3%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MLYS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MLYSMineralys Therapeutics, Inc.$2.2B
37
VERAVera Therapeutics, Inc.$2.2B
22
PHVSPharvaris NV$2.3B
46
COAGHemab Therapeutics Holdings, Inc.$2.2B
1
PGENPrecigen, Inc.$2.2B
68
NUVBNuvation Bio, Inc.$2.2B
75
VCELVericel Corp.$2.3B
94
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MLYS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest MLYS news & analysis

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 27 July 2026neutral

Mineralys Therapeutics granted inducement stock option and restricted stock unit awards totaling 42,800 shares and 32,100 shares, respectively, to two new non-executive employees on July 17 and July 20, 2026. The inducement awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The grants signal that Mineralys is hiring new non-executive talent, though the awards are standard inducements for new employees and do not reflect company performance or financial outlook.

FAQ

Frequently asked questions about MLYS stock

What is the MLYS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Mineralys Therapeutics, Inc. have a median 12-month price target of $52, with estimates ranging from $30 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MLYS stock a buy right now?

Of the 10 analysts covering Mineralys Therapeutics, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mineralys Therapeutics, Inc. 37 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MLYS?

As at 1 Aug 2026, Mineralys Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (70 of 100).

Will MLYS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +101.7% from the last close, and Ticker Nerd's factor model ranks Mineralys Therapeutics, Inc. 37 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MLYS stock forecast for 2030?

No analyst covering Mineralys Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MLYS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $56 over the next 12 months.

How has MLYS stock performed over the past year?

Mineralys Therapeutics, Inc. returned +88.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Mineralys Therapeutics, Inc. do?

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cardio-renal-metabolic syndrome diseases, particularly those driven by dysregulated aldosterone.

What is the latest news on MLYS?

The most recent item we track (GlobeNewsWire, 27 July 2026): "Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)". Mineralys Therapeutics granted inducement stock option and restricted stock unit awards totaling 42,800 shares and 32,100 shares, respectively, to two new non-executive employees on July 17 and July 20, 2026. The inducement awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

Company

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cardio-renal-metabolic syndrome diseases, particularly those driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor initially aimed at treating uncontrolled hypertension and resistant hypertension in patients not achieving blood pressure goals despite multiple antihypertensive medications. The company addresses unmet needs in hypertension, chronic kidney disease, obstructive sleep apnea, and related conditions where elevated aldosterone plays a key role, offering a novel mechanism to lower aldosterone levels by inhibiting the CYP11B2 enzyme. Mineralys Therapeutics, Inc. emphasizes precision in treatment, targeting patients with indicators like obesity that suggest aldosterone dependency. Led by an experienced management team and supported by expert scientific and board advisors in cardiovascular and renal diseases, the company advances its pipeline through clinical development. Founded in 2019 and headquartered in Radnor, Pennsylvania, Mineralys Therapeutics, Inc. plays a significant role in the biotechnology sector by innovating solutions for prevalent cardiometabolic disorders affecting millions worldwide.

CEO Dr. Jon Congleton · 76 employees · United States · https://mineralystx.com